'Disciplined Growth' Predicted for the Cell/Gene Therapy Business in 2026
Three California-funded firms cited as examples
The head of the leading national regenerative medicine industry association said this week that the field is “entering a very disciplined and, we believe, sustainable growth cycle.”
Timothy Hunt, the chief executive officer of the Alliance for Regenerative Medicine (ARM), spoke at a health industry conference (JPMorgan 2026) attended by 8,000 persons in San Francisco. He laid out his outlook to a smaller audience, one interested in cell and gene therapy, which is the purview of the California Institute for Regenerative Medicine (CIRM), which is spending billions of taxpayer dollars in those areas.
One of ARM’s “takeaways” said, “The current disciplined growth cycle is being driven by investors and strategic biopharma, with 2025 seeing $11.1 billion in investment, driven by a strong showing of venture financing and a more favorable public market.”
